---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-24-000002"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T07:43:16.294312+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q4 sales $1.53B (+14% YoY); 2024 guidance reiterated with higher TMTT outlook

## Summary
- Q4 2023 sales $1.53B (+14% reported, +13% constant currency); TAVR $979M (+13%).
- Q4 GAAP EPS $0.61, adjusted EPS $0.64; full-year 2023 EPS $2.30 (GAAP), $2.51 adjusted.
- TMTT sales $56M in Q4, $198M full year (+65% constant currency); EVOQUE received FDA approval for tricuspid regurgitation.
- 2024 guidance: sales $6.3-6.6B (8-10% constant currency growth), adjusted EPS $2.70-2.80; Q1 sales $1.53-1.61B.
- Repurchased $444M in Q4, $867M in 2023; $1B remaining authorization; cash $1.6B, debt $600M.

## SEC filing metadata
- accession: 0001099800-24-000002
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/ew-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-24-000002
- JSON: https://secwatch.observer/filing/0001099800-24-000002.json
- Plain text: https://secwatch.observer/filing/0001099800-24-000002.txt

## Key facts
- Earnings Releases
  Edwards Lifesciences Corp reported the year ended December 31, 2023 results: revenue $6.0 billion, EPS $2.30.
  - Period: the year ended December 31, 2023
  - Revenue: $6.0 billion
  - EPS: $2.30
  - Result: reported results
  source text: Sales for the year ended December 31, 2023, were $6.0 billion, a year-over-year increase of 12 percent on both a reported and constant currency basis. Diluted earnings per share for 2023 were $2.30, while adjusted earnings per share were $2.51 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm
- Earnings Releases
  Edwards Lifesciences Corp reported the quarter ended December 31, 2023 results: revenue $1.53 billion, EPS $0.61.
  - Period: the quarter ended December 31, 2023
  - Revenue: $1.53 billion
  - EPS: $0.61
  - Result: reported results
  source text: Feb. 6, 2024 — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook • Q4 sales grew 14 percent to $1.53 billion; constant currency 1 sales grew 13 percent • Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent • Q4 EPS of $0.61; adjusted 1 EPS of $0.64 • 2023 sales of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980024000002/0001099800-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.